Assessing cost-effectiveness analyses in rheumatoid arthritis and osteoarthritis

Arthritis and Rheumatism

Volumn 10, Issue 6, 1997, Pages 413-421

  Ruchlin, Hirsch S ^a,b   Elkin, Elena B ^a   Paget, Stephen A ^a,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Cost effectiveness; Economic efficacy

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HEALTH ECONOMICS; METHODOLOGY; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS;

EID: 84988220928     PISSN: 0004-3591     EISSN: 1529-0131     Source Type: Journal    
DOI: 10.1002/art.1790100609     Document Type: Article

References (35)

1. Yelin E, Callahan LF, for the National Arthritis Data Work Group. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995;38:1351-62.
2. Ruchlin HS, Allegrante JP, Einstein J, O'Doherty J, Robbins L, Peterson MGE, et al. A method for documenting the economic efficacy of multiple-component interventions designed to enhance functional and social status. Arthritis Care Res 1997;10:151-8.
3. Weinstein MC, Stasson W. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296:716-21.
4. Eisenberg JM. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 1989;262:2879-86.
5. Russell LB, Gold ME, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
6. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8.
7. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339-41.
8. Gold ME, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
9. Chang RW, Pellissier JM, Hazen GB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996;275:858-65,
10. Finkler SA. The distinction between cost and charges. Ann Intern Med 1982;96:102-9.
11. Ruchlin HS, Morris JM. The congregate housing services program: an analysis of service utilization and cost. Gerontologist 1987;27:87-91.
12. Berry RE, Boland JP. The economic cost of alcohol abuse. New York: Free Press; 1977.
13. Ruchlin HS, Elkin EB, MacKenzie CR, Williams-Russo P, Allegrante JP. Determining the cost of a clinical intervention through the use of shadow pricing. Arthritis Care Res 1997;10:343-51.
14. Thompson MS, Read JL, Hutchings HC, Paterson M, Harris ED Jr. The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 1988;15:35-42.
15. Anis AH, Tugwell PX, Wells GA, Stewart DG. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 1996;23:609-16.
16. Liang MH, Cullen KE, Larson MG, Thompson MS, Schwartz JA, Fossel AH, et al. Cost-effectiveness of total joint arthroplasty in osteoarthritis. Arthritis Rheum 1986;29:937-43.
17. Weinberger M, Tierney WM, Cowper PA, Katz BP, Booher PA. Cost-effectiveness of increased telephone contact for patients with osteoarthritis: a randomized controlled trial. Arthritis Rheum 1993;36:243-6.
18. Chang RW, Falconer J, Stulberg SD, Arnold WJ, Manheim LM, Dyer AR. A randomized, controlled trial of arthroscopic surgery versus closed-needle joint lavage for patients with osteoarthritis of the knee. Arthritis Rheum 1993;36:289-96.
19. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
20. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
21. Pincus T, Callahan L. The "side effects" of rheumatoid arthritis: joint destruction, disability, and early mortality. Br J Rheumatol 1993;32 Suppl 1:28-37.
22. Prashker MJ, Meenan RF. The total cost of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995;38:318-25.
23. Liang MH, Larson M, Thompson M, Eaton H, McNamara E, Katz R, et al. Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984;27:522-9.
24. Lubeck DP, Spitz PW, Fries JF, Wolfe F, Mitchell DM, Roth SH. A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 1986;29:488-93.
25. Allaire SH, DeNardo BS, Szer IS, Meenan RF, Schaller JG. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992;19:952-5.
26. Gabriel SE, Crowson CS, O'Fallon WM. Costs of osteoarthritis: estimates from a geographically defined population. J Rheumatol 1995;22 Suppl 43:23-5.
27. Yelin EH, Felts WR. A summary of the impact of musculoskeletal conditions in the United States. Arthritis Rheum 1990;33:750-5.
28. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988;84 Suppl 2A:20-4.
29. Stucki G, Johannesson M, Liang MH. Is misoprostol cost-effective in the prevention of nonsteroidal antiinflammatory drug-induced gastropathy in patients with chronic arthritis? Am J Med 1994;154:2020-5.
30. Gabriel SE, Campion ME, O'Fallon WM. A cost-utility analysis of misoprostol prophylaxis for rheumatoid arthritis patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 1994;37:333-41.
31. Greene JM, Winickoff RN. Cost-conscious prescribing of nonsteroidal anti-inflammatory drugs for adults with arthritis: a review and suggestions. Arch Intern Med 1992;152:1995-2002.
32. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol to prevent gastric ulcer in patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1989;149:2061-5.
33. Gabriel SE, Wagner JL. Costs and effectiveness of non-steroidal anti-inflammatory drugs: the importance of reducing side effects. Arthritis Care Res 1997;10:56-63.
34. Bergquist SR, Felson DT, Prashker MJ, Freedberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1995;38:326-31.
35. Erickson AR, Reddy V, Vogelgesang SA, West SG. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995;38:1115-9.